# Scenario run report

**LIVE run (real LLM; models: gemini-3.5-flash, gemini-3.1-flash-lite)**

Totals: 41 pass, 6 fail, 11 need human review, 2 hypotheses not confirmed.

Statuses: `pass`/`fail` are objective checks; `review` needs a human; `differs` means the agent did not confirm one of our written gap hypotheses.

## Event 1: Baseline records arrive from Hospitals A and C
*2026-11-02T09:00*

Fatima (72) has kidney disease, type 2 diabetes, hypertension and atrial fibrillation, and a recorded penicillin allergy. Cardiology (A) uploads warfarin and ramipril; endocrinology (C) uploads metformin. No lab results are on file yet.

| Area | Check | Expected | Actual | Status |
|---|---|---|---|---|
| safety | finding MISSING:DEMO-LAB-001:glucophage present | present | present | **pass** |
| safety | finding DEMO-INT-002 absent | absent | absent | **pass** |
| safety | no 'interaction' findings | none | none | **pass** |
| safety | no 'contraindication' findings | none | none | **pass** |
| safety | no 'lab-rule' findings | none | none | **pass** |
| consent | C_reads_A_meds | {'allowed': True, 'reason_code': 'GRANTED'} | {'allowed': True, 'reason_code': 'GRANTED', 'escalate': False} | **pass** |
| policy | expectation for human review | Metformin cannot be assessed without eGFR: flag as uncertain, do not guess. | see agent output (conflicts, caveats, gaps) | **review** |
| audit | audit trail has 'grant_created' | present | present | **pass** |
| audit | audit trail has 'access_decision' | present | present | **pass** |

## Event 2: Hospital B (Dubai) prescribes spironolactone
*2026-11-03T10:00*

Nephrology at Hospital B, in a different emirate, adds spironolactone. The patient already takes ramipril and has kidney disease. Neither hospital knows about the other's prescription unless data is shared.

| Area | Check | Expected | Actual | Status |
|---|---|---|---|---|
| safety | finding DEMO-INT-002 present | present | present | **pass** |
| safety | finding MISSING:DEMO-LAB-002:aldactone present | present | present | **pass** |
| safety | finding MISSING:DEMO-LAB-001:glucophage present | present | present | **pass** |
| safety | severity of DEMO-INT-002 | high | high | **pass** |
| consent | A_reads_B_meds | {'allowed': True, 'reason_code': 'GRANTED'} | {'allowed': True, 'reason_code': 'GRANTED', 'escalate': False} | **pass** |
| consent | B_reads_A_meds | {'allowed': True, 'reason_code': 'GRANTED'} | {'allowed': True, 'reason_code': 'GRANTED', 'escalate': False} | **pass** |
| policy | cites uae-health-ict-law-2019 ('confidentiality of health data') | cited | not cited | **fail** |
| policy | cites dha-health-info-sharing-2024 ('Consent must be obtained') | cited | not cited | **fail** |
| policy | cites doh-hie-policy-2020 ('Universal') | cited | ['doh-hie-policy-2020#0021'] | **pass** |
| policy | expectation for human review | Two emirate regimes apply (Abu Dhabi DoH and Dubai DHA); sharing here rests on the patient's grants. | see agent output (conflicts, caveats, gaps) | **review** |
| gap | GAP-CONSENT-REGIME-DIVERGENCE: hypothesis | Abu Dhabi's HIE policy (DoH 2020, s4.2) makes participation mandatory and authorizes sharing even when consent | likely match: 'Cross-Emirate HIE Consent Synchronization Rules' (no_provision_found) | **review** |
| audit | audit trail has 'access_decision' | present | present | **pass** |

**Policy agent** (5 searches, completed=True)
- *requirement:* Under UAE Federal Law Executive Regulations, disclosing a patient's health information to any party without the consent of the patient or their legal representative is legally prohibited, unless permitted by applicable legislation in force in the UAE. [uae-health-ict-exec-reg-2020#0007]
- *requirement:* Under Dubai Health Authority (DHA) Policy, sharing health information between non-affiliated entities in the UAE via Health Information Exchanges (NABIDH, Malaffi, Riayati) requires patient consent. [dha-health-info-sharing-2024#0015]
- *requirement:* Under DHA Standards, patient consent for accessing health information systems remains valid for one year following the patient's last health encounter, unless explicitly revoked. [dha-consent-access-standard-2025#0017]
- *requirement:* Under DHA Standards, patients must be informed of the potential consequences of not sharing health information and retain the right to withdraw consent and opt out, though withdrawal does not affect prior lawful access or incorporation of information into facility records. [dha-consent-access-standard-2025#0018]
- *requirement:* Under Abu Dhabi Department of Health (DoH) Policy, healthcare facilities are mandated to share patient data with the Abu Dhabi Health Information Exchange (Malaffi) under universal participation goals and must seek patient consent by incorporating standard consent wording into healthcare facility consent forms. [doh-hie-policy-2020#0021, doh-hie-policy-2020#0022]
- *gap (no_provision_found):* **Cross-Emirate HIE Consent Synchronization Rules**: The available text does not provide specific rules or technical standards governing how patient consent granted in one emirate's exchange (e.g., NABIDH in Dubai) is harmonized or legally operationalized across exchange platforms in another emirate (e.g., Malaffi in Abu Dhabi). [dha-health-info-sharing-2024#0015, doh-hie-policy-2020#0022]

## Event 3: Overdue lab results arrive three days late
*2026-11-06T16:00*

eGFR and potassium were taken on 3 Nov but only reach the system on 6 Nov. Until now the system had to treat both as unknown.

| Area | Check | Expected | Actual | Status |
|---|---|---|---|---|
| safety | finding DEMO-LAB-001:glucophage present | present | present | **pass** |
| safety | finding DEMO-LAB-002:aldactone present | present | present | **pass** |
| safety | finding DEMO-INT-002 present | present | present | **pass** |
| safety | finding MISSING:DEMO-LAB-001:glucophage absent | absent | absent | **pass** |
| safety | finding MISSING:DEMO-LAB-002:aldactone absent | absent | absent | **pass** |
| safety | severity of DEMO-LAB-001:glucophage | high | high | **pass** |
| safety | severity of DEMO-LAB-002:aldactone | high | high | **pass** |
| policy | expectation for human review | Earlier 'missing lab' uncertainty is resolved by the late result; the log must show both states. | see agent output (conflicts, caveats, gaps) | **review** |

Safety agent issues: Rejected explanation for DEMO-LAB-001:glucophage: contained forbidden medication advice; Rejected explanation for DEMO-LAB-002:aldactone: contained forbidden medication advice

## Event 4: Patient withdraws consent for Hospital B's data and opts out of NABIDH
*2026-11-07T11:00*

Fatima revokes every grant covering Hospital B's records and opts out of the Dubai exchange. From now on the platform must stop using Hospital B's data. Earlier sharing is already on record.

| Area | Check | Expected | Actual | Status |
|---|---|---|---|---|
| safety | finding DEMO-LAB-001:glucophage present | present | present | **pass** |
| safety | finding DEMO-INT-002 absent | absent | absent | **pass** |
| safety | finding DEMO-LAB-002:aldactone absent | absent | absent | **pass** |
| safety | limitation notice mentions HospitalB | present | present | **pass** |
| consent | A_reads_B_meds_direct | {'allowed': False, 'reason_code': 'REVOKED'} | {'allowed': False, 'reason_code': 'REVOKED', 'escalate': False} | **pass** |
| consent | A_reads_B_meds_exchange | {'allowed': False, 'reason_code': 'OPTED_OUT_OF_EXCHANGE'} | {'allowed': False, 'reason_code': 'OPTED_OUT_OF_EXCHANGE', 'escalate': False} | **pass** |
| policy | cites dha-consent-access-standard-2025 ('right to withdraw') | cited | ['dha-consent-access-standard-2025#0018'] | **pass** |
| policy | cites dha-consent-access-standard-2025 ('retain such information') | cited | ['dha-consent-access-standard-2025#0018'] | **pass** |
| policy | expectation for human review | The assessment is now incomplete by the patient's choice and must say so. | see agent output (conflicts, caveats, gaps) | **review** |
| policy | expectation for human review | Information already shared may stay in recipients' records. | see agent output (conflicts, caveats, gaps) | **review** |
| gap | GAP-CONSENT-REGIME-DIVERGENCE: hypothesis | Abu Dhabi's HIE policy (DoH 2020, s4.2) makes participation mandatory and authorizes sharing even when consent | not raised by the agent (hypothesis not confirmed) | **differs** |
| audit | audit trail has 'grant_revoked' | present | present | **pass** |
| audit | audit trail has 'exchange_opt_out' | present | present | **pass** |
| audit | audit trail has 'access_decision' | present | present | **pass** |

**Policy agent** (1 searches, completed=True)
- *requirement:* In Dubai, the withdrawal of consent does not affect any sharing of health information that was carried out under consent prior to the withdrawal. [dha-consent-access-standard-2025#0018]
- *requirement:* Entities that have accessed or received health information via the Health Information System (HIS) prior to the revocation of consent and have incorporated such information into their own records may retain that information. [dha-consent-access-standard-2025#0018]
- *requirement:* Patients have the right to withdraw consent and opt-out of the NABIDH exchange after being informed of the potential consequences of not sharing information. [dha-consent-access-standard-2025#0018]
- *requirement:* Upon a patient's request, the DHA NABIDH team is responsible for opting the patient out of the NABIDH exchange. [dha-consent-access-standard-2025#0019]
- *comparison:* Under the EU EHDS, Member States may provide for an absolute right to opt out of access to personal electronic health data by anyone other than the original controller, and may establish specific rules regarding medical liability in cases where such restrictions are placed by the patient. [eu-ehds-2025-327#0011]
- *gap (no_provision_found):* **Effect on future clinical safety assessments**: The provided texts do not explicitly state the legal or clinical liability implications for healthcare providers when a patient's opt-out or withdrawal of consent results in incomplete data for safety assessments (e.g., drug-drug interaction checks). []

Safety agent issues: Rejected explanation for DEMO-LAB-001:glucophage: contained forbidden medication advice

## Event 5: Emergency: clinician at Hospital A requests Hospital B's medication list
*2026-11-08T02:30*

Fatima arrives unconscious at Hospital A with bleeding. The doctor needs her full medication list, including Hospital B's, and requests break-the-glass access. She has opted out of NABIDH.

| Area | Check | Expected | Actual | Status |
|---|---|---|---|---|
| safety | finding DEMO-LAB-001:glucophage present | present | present | **pass** |
| safety | finding DEMO-INT-002 absent | absent | absent | **pass** |
| consent | ED_btg_B_meds | {'allowed': False, 'reason_code': 'EMERGENCY_BLOCKED_BY_OPT_OUT', 'escalate': True} | {'allowed': False, 'reason_code': 'EMERGENCY_BLOCKED_BY_OPT_OUT', 'escalate': True} | **pass** |
| policy | cites uae-health-ict-law-2019 ('health and safety of the patient') | cited | not cited | **fail** |
| policy | cites dha-consent-access-standard-2025 ('should not be retrieved using BTG') | cited | not cited | **fail** |
| policy | cites dha-consent-access-standard-2025 ('emergency condition') | cited | not cited | **fail** |
| policy | cites dha-consent-access-standard-2025 ('Emirate of Dubai') | cited | not cited | **fail** |
| policy | expectation for human review | Federal Art. 16(3) health-and-safety exception conflicts with DHA 9.7 opt-out rule. | see agent output (conflicts, caveats, gaps) | **review** |
| policy | expectation for human review | The system must escalate to a human and must not silently override either rule. | see agent output (conflicts, caveats, gaps) | **review** |
| gap | GAP-CROSS-EMIRATE-EMERGENCY-ACCESS: hypothesis | DHA's break-the-glass rules cover Dubai entities and bar BTG retrieval for opted-out patients (s9.7), while fe | not raised by the agent (hypothesis not confirmed) | **differs** |
| audit | audit trail has 'access_decision' | present | present | **pass** |

**Escalated to a human:** Emergency access was not granted because the patient opted out of NABIDH. A human decision is required.

**Policy agent** (4 searches, completed=True)
- *requirement:* In Dubai, 'Break The Glass' is defined as a mechanism allowing health professionals to gain access to protected health information (PHI) in the health information system (HIS) without the patient's consent. [dha-consent-access-standard-2025#0004]
- *requirement:* In Abu Dhabi, authorized users may 'break the seal' if they determine in their reasonable judgment that the patient is in immediate need of medical attention and the information held by or accessible via the ADHIE platform may be material to emergency treatment. [doh-hie-policy-2020#0054]
- *comparison:* Under EU law (EHDS), Member States may provide for an absolute right to opt out from access to personal electronic health data by anyone other than the original controller, without any possibility to override that opt-out in emergency situations. [eu-ehds-2025-327#0011]
- *gap (no_provision_found):* **Emergency access to opted-out records**: The provided texts do not contain the specific provision 'section 9.7' of DHA/HISHD/ST-09 mentioned in the scenario, nor do they explicitly state the rules for overriding an opt-out status during an emergency for cross-emirate data requests. []

Safety agent issues: Rejected explanation for DEMO-LAB-001:glucophage: contained forbidden medication advice

## Event 6: Who owns the follow-up?
*2026-11-08T09:00*

With eGFR 24 and potassium 5.4 on record, Hospital C asks which institution is responsible for coordinating the response across three prescribers in two emirates.

| Area | Check | Expected | Actual | Status |
|---|---|---|---|---|
| safety | finding DEMO-LAB-001:glucophage present | present | present | **pass** |
| safety | finding DEMO-INT-002 absent | absent | absent | **pass** |
| safety | limitation notice mentions HospitalB | present | present | **pass** |
| policy | expectation for human review | If no provision assigning cross-institution responsibility is found in the ingested KB, say so and list what w | see agent output (conflicts, caveats, gaps) | **review** |
| policy | expectation for human review | Absence in the KB is not proof that no rule exists elsewhere. | see agent output (conflicts, caveats, gaps) | **review** |
| gap | GAP-CROSS-INSTITUTION-RESPONSIBILITY: hypothesis | Hypothesis: no ingested provision assigns responsibility for coordinating follow-up on medication findings tha | likely match: 'Responsibility for cross-emirate medication safety coordination' (no_provision_found) | **review** |

**Policy agent** (1 searches, completed=True)
- *comparison:* The EU EHDS regulation (Article 20) provides a mechanism for designating a lead authority when multiple digital health authorities exist within a Member State, requiring one to be responsible for reporting and coordinating information from others. [eu-ehds-2025-327#0107]
- *gap (no_provision_found):* **Responsibility for cross-emirate medication safety coordination**: There is no provision in the provided knowledge base that specifies which institution is responsible for coordinating follow-up on high-severity medication safety findings when the involved prescribers operate across different emirates (e.g., Abu Dhabi and Dubai). []

Safety agent issues: Rejected explanation for DEMO-LAB-001:glucophage: contained forbidden medication advice
